How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 20 09 2019
accepted: 09 05 2020
pubmed: 20 5 2020
medline: 20 2 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

To investigate whether prostate cancer (PCa) patients' coping strategies (i.e., fighting spirit, anxious preoccupation, fatalism, helplessness/hopelessness, and avoidance) significantly change during the first 3-year follow-up period of active surveillance (AS). Altogether, 104 patients on AS completed the Mini-Mental Adjustment to Cancer (Mini-MAC) at baseline (T0), at 10 and 12 months after diagnostic biopsy (T1 and T2, respectively) and then at 24- (T3) and 36-month (T4) follow-up. Paired samples T test was used to detect statistically significant changes over time. Changes ≥ 1 point (or ≤ - 1) were hypothesized to be clinically relevant. During the first 3 years on AS, men experienced decreased anxiety, avoidance thoughts/behaviors, and fight-against-cancer attitudes, and these changes were found to be statistically significant. When considering clinically significant changes between inclusion in AS (T0) and 3-year follow-up (T4), avoidance decreased in 19% of patients. Most patients were observed to have adopted functional coping strategies at baseline, which were maintained through the first 3 years on AS. Overall, men on AS may perceive increasing control over their cancer and comfort with the AS protocol over time and experience slight decreases in anxious preoccupation, cancer-related avoidance thoughts and behaviors, and fight-against-cancer reactions. For those men who find it difficult to cope with AS, psychological monitoring and interventions could be helpful throughout the monitoring journey.

Identifiants

pubmed: 32424643
doi: 10.1007/s00520-020-05524-8
pii: 10.1007/s00520-020-05524-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

645-651

Subventions

Organisme : Fondazione Italo Monzino
ID : not available
Organisme : Associazione Italiana Ricerca sul Cancro
ID : AIRC IG16087

Références

Best M, Aldridge L, Butow P, Olver I, Webster F (2015) Conceptual analysis of suffering in cancer: a systematic review. Psycho-oncology 24(9):977–986
pubmed: 25754062 doi: 10.1002/pon.3795
Sharpley CF, Bitsika V, Christie DR (2018) “The Worst Thing Was…”: prostate cancer patients’ evaluations of their diagnosis and treatment experiences. Am J Mens Health 12(5):1503–1509
pubmed: 29708020 pmcid: 6142165 doi: 10.1177/1557988318772752
Davison BJ, Degner LF (1997) Empowerment of men newly diagnosed with prostate cancer. Cancer Nurs 20:187–196
pubmed: 9190093 doi: 10.1097/00002820-199706000-00004
Linden W, Vodermaier A, MacKenzie R, Greig D (2012) Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 141(2):343–351
pubmed: 22727334 doi: 10.1016/j.jad.2012.03.025
Folkman S, Lazarus RS (1984) Stress, appraisal, and coping. Springer Publishing Company, New York, pp 150–153
Watson M, Young J, Inayat Q, Burgess C, Robertson B (1988) Development of a questionnaire measure of adjustment to cancer: the MAC scale. Psychol Med 18(1):203–209
pubmed: 3363039 doi: 10.1017/S0033291700002026
Folkman S, Lazarus RS (1980) An analysis of coping in a middle-aged community sample. J Health Soc Behav 21(3):219–239
pubmed: 7410799 doi: 10.2307/2136617
Roesch SC, Adams L, Hines A, Palmores A, Vyas P, Tran C, Pekin S, Vaughn AA (2005) Coping with prostate cancer: a meta-analytic review. J Behav Med 28(3):281–293
pubmed: 16015462 doi: 10.1007/s10865-005-4664-z
Greer S, Moorey S, Watson M (1989) Patients’ adjustment to cancer: the mental adjustment to cancer (MAC) scale vs clinical ratings. J Psychosom Res 33(3):373–377
pubmed: 2795510 doi: 10.1016/0022-3999(89)90027-5
O’Brien CW, Moorey S (2010) Outlook and adaptation in advanced cancer: a systematic review. Psychooncology 19(12):1239–1249
pubmed: 20200856 doi: 10.1002/pon.1704
Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, Holmberg L, Scandinavian Prostatic Cancer Group Study Number 4 (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347:790–796
pubmed: 12226149 doi: 10.1056/NEJMoa021483
Bellardita L, Valdagni R, Van Den Bergh R, Randsdorp H, Repetto C, Venderbos LDF et al (2015) How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol 67(4):637–645
pubmed: 25454617 doi: 10.1016/j.eururo.2014.10.028
Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ (2016) A decade of active surveillance in the PRIAS study. Eur Urol 70(6):954–960
pubmed: 27329565 doi: 10.1016/j.eururo.2016.06.007
Marenghi C, Alvisi MF, Palorini F, Avuzzi B, Badenchini F, Bedini N et al (2017) Eleven-year management of prostate cancer patients on active surveillance: what have we learned? Tumori 103(5):464–474
pubmed: 28623636 pmcid: 6379800 doi: 10.5301/tj.5000649
Bangma CH, Valdagni R, Carroll PR, Van Poppel H, Klotz L, Hugosson J (2015) Active surveillance for low-risk prostate cancer: developments to date. Eur Urol 67(4):646–648
pubmed: 25435266 doi: 10.1016/j.eururo.2014.11.004
Venderbos LD, Brandhof SD, Korfage IJ (2018) How does QoL compare between surveillance and active treatment? In: Klotz L (ed) Active surveillance for localized prostate cancer. Humana Press, Cham, pp 169–181
doi: 10.1007/978-3-319-62710-6_15
Venderbos LD, Aluwini S, Roobol MJ, Bokhorst LP, Oomens EH, Bangma CH, Korfage IJ (2017) Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. Qual Life Res 26(6):1635–1645
pubmed: 28168601 pmcid: 5420369 doi: 10.1007/s11136-017-1507-7
Venderbos LD, Van Den Bergh RC, Roobol MJ, Schröder FH, Essink-Bot ML, Bangma CH et al (2015) A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psychooncology 24(3):348–354
pubmed: 25138075 doi: 10.1002/pon.3657
Daubenmier JJ, Weidner G, Marlin R, Crutchfield L, Dunn-Emke S, Chi C et al (2006) Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology 67(1):125–130
pubmed: 16413347 doi: 10.1016/j.urology.2005.07.056
Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N et al (2016) Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol 13(3):151–167
pubmed: 26813955 doi: 10.1038/nrurol.2015.313
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71
pubmed: 21056534 doi: 10.1016/j.eururo.2010.10.039
Klotz L (2012) Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Urol Rep 13(2):153–159
pubmed: 22477615 doi: 10.1007/s11934-012-0242-4
Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8(2):162–200. https://doi.org/10.6004/jnccn.2010.0012
Villa S, Alvisi MF, Rancati T, Delor JPM, Avuzzi B, Bosetti D, Marenghi C, Magnani T, Morlino S, Salvioni R, Nicolai N, Torelli T, Valdagni R, Bellardita L (2016) Facing untreated prostate cancer on active surveillance: who is at risk for increased anxiety? Anticancer Res 36(5):2565–2566
Bellardita L, Rancati T, Alvisi MF, Villani D, Magnani T, Marenghi C, Nicolai N, Procopio G, Villa S, Salvioni R, Valdagni R (2013) Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol 64(1):30–36
pubmed: 23357351 doi: 10.1016/j.eururo.2013.01.009
Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P et al (2017) Setting an agenda for assessment of health-related quality of life among men with prostate cancer on active surveillance: a consensus paper from a European School of Oncology task force. Eur Urol 71(2):274–280
pubmed: 27720532 doi: 10.1016/j.eururo.2016.09.041
Mader EM, Li HH, Lyons KD, Morley CP, Formica MK, Perrapato SD et al (2017) Qualitative insights into how men with low-risk prostate cancer choosing active surveillance negotiate stress and uncertainty. BMC Urol 17(1):1–8
doi: 10.1186/s12894-017-0225-3
Yanez B, Bustillo NE, Antoni MH, Lechner SC, Dahn J, Kava B, Penedo FJ (2015) The importance of perceived stress management skills for patients with prostate cancer in active surveillance. J Behav Med 38(2):214–223
pubmed: 25234859 doi: 10.1007/s10865-014-9594-1
Grassi L, Buda P, Cavana L, Annunziata MA, Torta R, Varetto A (2005) Styles of coping with cancer: the Italian version of the Mini-Mental Adjustment to Cancer (Mini-MAC) scale. Psychooncology 14(2):115–124
pubmed: 15386782 doi: 10.1002/pon.826
Folkman S, Lazarus RS, Dunkel-Schetter C, DeLongis A, Gruen RJ (1986) Dynamics of a stressful encounter. Cognitive appraisal, coping, and encounter outcomes. J Pers Soc Psychol 50(5):992–1003
pubmed: 3712234 doi: 10.1037/0022-3514.50.5.992
Billings AG, Moos RH (1984) Coping, stress, and social resources among adults with unipolar depression. J Pers Soc Psychol 46(4):877–891
pubmed: 6737198 doi: 10.1037/0022-3514.46.4.877
Billings AG, Moos RH (1981) The role of coping responses and social resources in attenuating the stress of life events. J Behav Med 4(2):139–157
pubmed: 7321033 doi: 10.1007/BF00844267
Pearlin LI, Schooler C (1978) The structure of coping. J Health Soc Behav 19(1):2–21
pubmed: 649936 doi: 10.2307/2136319
Lashbrook MP, Valery PC, Knott V, Kirshbaum MN, Bernardes CM (2018) Coping strategies used by breast, prostate, and colorectal cancer survivors: a literature review. Cancer Nurs 41(5):E23–E39
pubmed: 28723724 doi: 10.1097/NCC.0000000000000528

Auteurs

Paola Dordoni (P)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy. paola.dordoni@istitutotumori.mi.it.

Fabio Badenchini (F)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Maria Francesca Alvisi (MF)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Julia Menichetti (J)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Letizia De Luca (L)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Teresa Di Florio (T)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Tiziana Magnani (T)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Cristina Marenghi (C)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Tiziana Rancati (T)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Riccardo Valdagni (R)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy.
Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Lara Bellardita (L)

Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH